DK3630726T3 - Krystallinske faste former af salte af n-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-n'-(4-fluorphenyl) cyclopropan-1,1-dicarboxamid, processer til fremstilling og fremgangsmåder til anvendelse - Google Patents

Krystallinske faste former af salte af n-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-n'-(4-fluorphenyl) cyclopropan-1,1-dicarboxamid, processer til fremstilling og fremgangsmåder til anvendelse Download PDF

Info

Publication number
DK3630726T3
DK3630726T3 DK18732548.5T DK18732548T DK3630726T3 DK 3630726 T3 DK3630726 T3 DK 3630726T3 DK 18732548 T DK18732548 T DK 18732548T DK 3630726 T3 DK3630726 T3 DK 3630726T3
Authority
DK
Denmark
Prior art keywords
crystallinic
dimethoxyquinolin
dicarboxamide
cyclopropane
fluorophenyl
Prior art date
Application number
DK18732548.5T
Other languages
Danish (da)
English (en)
Inventor
Khalid Shah
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62683441&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3630726(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Exelixis Inc filed Critical Exelixis Inc
Application granted granted Critical
Publication of DK3630726T3 publication Critical patent/DK3630726T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
DK18732548.5T 2017-05-26 2018-05-26 Krystallinske faste former af salte af n-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-n'-(4-fluorphenyl) cyclopropan-1,1-dicarboxamid, processer til fremstilling og fremgangsmåder til anvendelse DK3630726T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762511714P 2017-05-26 2017-05-26
PCT/US2018/034784 WO2018218233A1 (en) 2017-05-26 2018-05-26 Crystalline solid forms of salts of n-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-n'-(4-fluorphenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use

Publications (1)

Publication Number Publication Date
DK3630726T3 true DK3630726T3 (da) 2022-03-07

Family

ID=62683441

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18732548.5T DK3630726T3 (da) 2017-05-26 2018-05-26 Krystallinske faste former af salte af n-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-n'-(4-fluorphenyl) cyclopropan-1,1-dicarboxamid, processer til fremstilling og fremgangsmåder til anvendelse

Country Status (20)

Country Link
US (3) US11279675B2 (enExample)
EP (1) EP3630726B1 (enExample)
JP (3) JP7166292B2 (enExample)
KR (1) KR102611445B1 (enExample)
CN (1) CN110621662B (enExample)
AU (1) AU2018272088C1 (enExample)
CA (1) CA3060370A1 (enExample)
DK (1) DK3630726T3 (enExample)
EA (1) EA039654B1 (enExample)
ES (1) ES2909390T3 (enExample)
HU (1) HUE058196T2 (enExample)
IL (1) IL270780B2 (enExample)
MA (1) MA48776A (enExample)
MX (1) MX2019012505A (enExample)
PL (1) PL3630726T3 (enExample)
PT (1) PT3630726T (enExample)
SG (1) SG11201909161PA (enExample)
UA (1) UA127760C2 (enExample)
WO (1) WO2018218233A1 (enExample)
ZA (1) ZA201906127B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015218236B2 (en) * 2014-02-14 2019-06-13 Exelixis, Inc. Crystalline solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use
IL270780B2 (en) * 2017-05-26 2025-04-01 Exelixis Inc Crystalline solid forms of salts of N–{4–[(7,6–dimethoxyquinolin–4–yl)oxy]phenyl}–N'–(4–fluorophenyl)cyclopropane–1,1–dicarboxamide, processes for preparation and methods of use
GEAP202415420A (en) 2018-01-26 2024-12-25 Exelixis Inc Compounds for the treatment of kinase-dependent disorders
CN120305263A (zh) 2018-06-15 2025-07-15 汉达癌症医药责任有限公司 卡博替尼的盐类于制备治疗癌症的剂型的用途
EP4631505A3 (en) * 2018-12-13 2025-12-10 Exelixis, Inc. Crystalline forms and salt forms of a kinase inhibitor
SG11202111978VA (en) * 2019-06-03 2021-11-29 Exelixis Inc Crystalline salt forms of a kinase inhibitor
WO2023165948A1 (en) 2022-03-01 2023-09-07 Synthon B.V. Cabozantinib salt with l-(+)-tartaric acid and solid forms thereof
AU2024215796A1 (en) 2023-01-31 2025-05-15 Handa Oncology, Llc Improved cabozantinib compositions and methods of use
US11814356B1 (en) 2023-03-29 2023-11-14 Apotex Inc. Salt of cabozantinib

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2744997A1 (en) 2003-09-26 2005-04-07 Exelixis, Inc. C-met modulators and method of use
EA038195B1 (ru) 2009-01-16 2021-07-22 Экселиксис, Инк. Малатная соль n-(4-{[6,7-бис-(метилокси)хинолин-4-ил]окси}фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида и ее применение для лечения рака почек и печени
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
US20120070368A1 (en) 2010-04-16 2012-03-22 Exelixis, Inc. Methods of Using C-Met Modulators
WO2012009722A1 (en) 2010-07-16 2012-01-19 Exelixis, Inc. C-met modulator pharmaceutical compositions
CN103391773A (zh) 2010-09-27 2013-11-13 埃克塞里艾克西斯公司 用于治疗去势抵抗性前列腺癌和成骨性骨转移的met和vegf的双重抑制剂
DK2621481T4 (da) 2010-09-27 2023-01-09 Exelixis Inc Dobbelte inhibitorer af MET og VEGF til behandling af kastrationsresistent prostatacancer og osteoblastiske knoglemetastaser
TWI640509B (zh) 2011-02-10 2018-11-11 艾克塞里克斯公司 製造喹啉化合物之方法及包含該化合物之醫藥組合物
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
TWI610918B (zh) 2011-05-02 2018-01-11 艾克塞里克斯公司 治療癌症及骨癌疼痛之方法
GEP201606523B (en) 2011-09-22 2016-08-10 Exelixis Inc Method for treating osteoporosis
WO2013066296A1 (en) 2011-10-31 2013-05-10 Hewlett-Packard Development Company, L.P. Method of fabricating a color filter array using a multilevel structure
EP2776033A1 (en) 2011-11-08 2014-09-17 Exelixis, Inc. Dual inhibitor of met and vegf for treating cancer
EP2775921A1 (en) 2011-11-08 2014-09-17 Exelixis, Inc. Method of quantifying cancer treatment
CN104649969B (zh) 2013-11-22 2019-02-12 广东东阳光药业有限公司 一种替尼类药物的盐及其制备方法
AU2015218236B2 (en) * 2014-02-14 2019-06-13 Exelixis, Inc. Crystalline solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use
WO2015177758A1 (en) * 2014-05-23 2015-11-26 Mylan Laboratories Ltd Novel polymorphs of cabozantinib (s)-malate and cabozantinib free base
CN104961680B (zh) 2014-11-07 2017-09-12 苏州晶云药物科技有限公司 N‑(4‑{[6,7‑双(甲基氧基)喹啉‑4‑基]氧基}苯基)‑n’‑(4‑氟苯基)环丙烷‑1,1‑二甲酰胺的盐酸盐及其多晶型
CN104961681B (zh) 2014-11-13 2017-06-13 苏州晶云药物科技有限公司 卡博替尼的粘酸盐及其晶型
EP3274333B1 (en) * 2015-03-25 2019-04-24 Sandoz AG Cabozantinib salts and their use as anti-cancer agents
WO2016150966A1 (en) 2015-03-25 2016-09-29 Sandoz Ag Crystalline forms of cabozantinib phosphate and cabozantinib hydrochloride
US10980792B2 (en) * 2016-09-12 2021-04-20 Zhuhai Beihai Biotech Co., Ltd. Formulations of Cabozantinib
WO2018104954A1 (en) * 2016-12-07 2018-06-14 Msn Laboratories Private Limited, R&D Center Process for the preparation of n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide, (2s)-hydroxybutanedioate and its polymorphs thereof
IL270780B2 (en) * 2017-05-26 2025-04-01 Exelixis Inc Crystalline solid forms of salts of N–{4–[(7,6–dimethoxyquinolin–4–yl)oxy]phenyl}–N'–(4–fluorophenyl)cyclopropane–1,1–dicarboxamide, processes for preparation and methods of use

Also Published As

Publication number Publication date
MA48776A (fr) 2020-04-08
KR20200010205A (ko) 2020-01-30
JP7166292B2 (ja) 2022-11-07
US20220162166A1 (en) 2022-05-26
CN110621662A (zh) 2019-12-27
CA3060370A1 (en) 2018-11-29
AU2018272088C1 (en) 2022-09-22
ZA201906127B (en) 2022-11-30
EA039654B1 (ru) 2022-02-22
EP3630726A1 (en) 2020-04-08
US11279675B2 (en) 2022-03-22
EA201992803A1 (ru) 2020-04-16
JP2022145852A (ja) 2022-10-04
US11731941B2 (en) 2023-08-22
IL270780B1 (en) 2024-12-01
US20210261509A1 (en) 2021-08-26
JP2020521732A (ja) 2020-07-27
EP3630726B1 (en) 2021-12-22
IL270780B2 (en) 2025-04-01
WO2018218233A1 (en) 2018-11-29
UA127760C2 (uk) 2023-12-27
CN110621662B (zh) 2023-06-23
AU2018272088B2 (en) 2022-06-16
SG11201909161PA (en) 2019-10-30
AU2018272088A8 (en) 2019-10-24
IL270780A (en) 2020-01-30
NZ757564A (en) 2025-05-02
HUE058196T2 (hu) 2022-07-28
JP7437460B2 (ja) 2024-02-22
JP2024036690A (ja) 2024-03-15
JP7659097B2 (ja) 2025-04-08
ES2909390T3 (es) 2022-05-06
US20240010621A1 (en) 2024-01-11
MX2019012505A (es) 2019-12-19
PT3630726T (pt) 2022-03-02
PL3630726T3 (pl) 2022-05-09
AU2018272088A1 (en) 2019-10-17
US12227481B2 (en) 2025-02-18
KR102611445B1 (ko) 2023-12-06

Similar Documents

Publication Publication Date Title
BR112016018450A2 (pt) formas sólidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida, processos de preparo e métodos de uso
IL270780A (en) Crystalline solid forms of salts of n-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-n'-(4-fluorphenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
JOP20250289A1 (ar) صور بلورية جديدة
DK3814357T3 (da) Heterocykliske og heteroarylforbindelser til behandling af huntingtons sygdom
EA201591756A1 (ru) Метаболиты n-(4-{[6,7-бис-(метилокси)хинолин-4-ил]окси}фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида
DK3713919T3 (da) Krystallinske former af n-(4-(4-(cyclopropylmethyl)piperazin-1-carbonyl)phenyl)quinolin-8-sulfonamid
EA201891742A1 (ru) Замещенное пиперидиновое соединение и его применение
MA47494A (fr) Nouvelles utilisations d'anticorps anti-sirpg
EP3536698A4 (en) LANOSTEROLPRODRUG COMPOUND AND MANUFACTURING METHOD THEREFOR AND USE THEREOF
UA122528C2 (uk) Сполуки, які модулюють fxr (nr1h4)
EA201691850A1 (ru) Дозирование составов, содержащих кабозантиниб
EP3551612A4 (en) PROCESS FOR THE PREPARATION OF N- (4- (6,7-DIMETHOXYQUINOLIN-4-YLOXY) PHENYL) -N '- (4-FLUOROPHENYL) CYCLOPROPANE-1, 1-DICARBOXAMIDE, (2S) -HYDROXYBUTANYEDIOOR AND ITS POLYDROXYBUTANYMATE
DK3700529T3 (da) Ny kombination af aktive midler til behandling af progressive fibroserende interstitielle lungesygdomme (pf-ild)
EP3572409A4 (en) 1,3,5-TRIAZINE DERIVATIVE SALT, CRYSTAL, PRODUCTION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF
EA201891644A1 (ru) Антибактериальные соединения и их применение
MA44672A (fr) Procédé de traitement du cancer à cellules rénales à l'aide de n-(4-(6,7-diméthoxyquinolin-4-yloxy) phényl)-n'-(4-fluorophény)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
EA201890570A1 (ru) [4-(1,3,3-триметил-2-оксо-3,4-дигидро-1h-хиноксалин-7-ил)фенокси]этилокси соединение или его соль
BR112018006866A2 (pt) compostos agonistas de ppar, composições farmacêuticas e métodos de uso dos mesmos
HUE063043T2 (hu) Eljárás N-(5-(4-(4-formil-3-fenil-1H-pirazol-1-il)-pirimidin-2-il-amino)-4-metoxi-2-morfolinofenil)-akrilamid elõállítására
EP3639845C0 (en) Il-15 protein complex pharmaceutical composition and uses thereof
DK3752497T3 (da) P300/cbp-hat-hæmmere
IL281923A (en) Compositions useful for treating gm1 gangliosidosis
EP3594216A4 (en) FIVE-PIECE HETEROCYCLIC AMINOPYRIMIDINE COMPOUND AND INTERMEDIATE PRODUCT, PRODUCTION METHOD, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF
EA201990158A1 (ru) Производные бензодиоксана и их фармацевтическое применение
EP3419988A4 (en) NEW PRNA TRIPLE CONNECTIONS